343 related articles for article (PubMed ID: 35066781)
1. A systematic review of multimodal clinical biomarkers in the management of thyroid eye disease.
Poon SHL; Cheung JJ; Shih KC; Chan YK
Rev Endocr Metab Disord; 2022 Jun; 23(3):541-567. PubMed ID: 35066781
[TBL] [Abstract][Full Text] [Related]
2. Knowledge of Thyroid Eye Disease in Graves' Disease Patients With and Without Orbitopathy.
Edmunds MR; Boelaert K
Thyroid; 2019 Apr; 29(4):557-562. PubMed ID: 30688164
[TBL] [Abstract][Full Text] [Related]
3. Tears as a Source of Biomarkers in the Diagnosis of Graves' Orbitopathy.
Bajkowska D; Szelachowska M; Buczyńska A; Krętowski AJ; Siewko K
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358969
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Utility of a New Assay for Thyroid Stimulating Immunoglobulins in Graves' Disease and Thyroid Eye Disease.
Stan MN; Algeciras-Schimnich A; Murthy V; Thapa P; Araki N
Thyroid; 2022 Feb; 32(2):170-176. PubMed ID: 34714163
[No Abstract] [Full Text] [Related]
5. [Treatment of Graves' disease in patients with thyroid eye disease].
Sviridenko NY; Sheremeta MS; Belovalova IM; Melnichenko GA
Vestn Oftalmol; 2021; 137(6):128-135. PubMed ID: 34965078
[TBL] [Abstract][Full Text] [Related]
6. Molecular Biomarkers in Thyroid Eye Disease: A Literature Review.
Ueland HO; Neset MT; Methlie P; Ueland GÅ; Pakdel F; Rødahl E
Ophthalmic Plast Reconstr Surg; 2023 Dec; 39(6S):S19-S28. PubMed ID: 38054982
[TBL] [Abstract][Full Text] [Related]
7. Potential involvement of the bone marrow in experimental Graves' disease and thyroid eye disease.
Gulbins A; Horstmann M; Keitsch S; Soddemann M; Wilker B; Wilson GC; Zeidan R; Hammer GD; Daser A; Bechrakis NE; Görtz GE; Eckstein A
Front Endocrinol (Lausanne); 2023; 14():1252727. PubMed ID: 37810891
[TBL] [Abstract][Full Text] [Related]
8. [Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?].
Wall JR; Lahooti H
Endokrynol Pol; 2011; 62 Suppl 1():1-7. PubMed ID: 22125104
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy.
Aass C; Norheim I; Eriksen EF; Børnick EC; Thorsby PM; Pepaj M
PLoS One; 2017; 12(4):e0175274. PubMed ID: 28419103
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases?
Wall JR; Lahooti H
Endokrynol Pol; 2010; 61(2):222-7. PubMed ID: 20464711
[TBL] [Abstract][Full Text] [Related]
11. Novel inflammatory biomarkers in thyroid eye disease.
Ueland HO; Ueland GÅ; Løvås K; Breivk LE; Thrane AS; Meling Stokland AE; Rødahl E; Husebye ES
Eur J Endocrinol; 2022 Aug; 187(2):293-300. PubMed ID: 35675127
[TBL] [Abstract][Full Text] [Related]
12. Socioeconomic Disparities in the Presentation and Treatment of Graves' Disease and Thyroid Eye Disease.
Vargason CW; Chelnis JG; Barahimi BI; Mawn LA
Semin Ophthalmol; 2016; 31(4):409-14. PubMed ID: 27385363
[TBL] [Abstract][Full Text] [Related]
13. Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease.
Gulbins A; Horstmann M; Daser A; Flögel U; Oeverhaus M; Bechrakis NE; Banga JP; Keitsch S; Wilker B; Krause G; Hammer GD; Spencer AG; Zeidan R; Eckstein A; Philipp S; Görtz GE
Front Endocrinol (Lausanne); 2023; 14():1211473. PubMed ID: 37435490
[TBL] [Abstract][Full Text] [Related]
14. Computed tomography and magnetic resonance imaging approaches to Graves' ophthalmopathy: a narrative review.
Luccas R; Riguetto CM; Alves M; Zantut-Wittmann DE; Reis F
Front Endocrinol (Lausanne); 2023; 14():1277961. PubMed ID: 38260158
[TBL] [Abstract][Full Text] [Related]
15. Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Patrizio A; Camastra S; Miccoli M; Cavallini G; Benvenga S; Antonelli A
Front Endocrinol (Lausanne); 2021; 12():654473. PubMed ID: 33935970
[TBL] [Abstract][Full Text] [Related]
16. Comparative assessment of Graves' disease and main extrathyroidal manifestation, Graves' ophthalmopathy, by non-targeted metabolite profiling of blood and orbital tissue.
Ji DY; Park SH; Park SJ; Kim KH; Ku CR; Shin DY; Yoon JS; Lee DY; Lee EJ
Sci Rep; 2018 Jun; 8(1):9262. PubMed ID: 29915201
[TBL] [Abstract][Full Text] [Related]
17. Tear-derived exosomal biomarkers of Graves' ophthalmopathy.
Shi TT; Zhao RX; Xin Z; Hou ZJ; Wang H; Xie RR; Li DM; Yang JK
Front Immunol; 2022; 13():1088606. PubMed ID: 36561758
[TBL] [Abstract][Full Text] [Related]
18. [Monoclonal antibodies in the treatment of thyroid eye disease].
Cheredanova VR; Poteshkin YE
Vestn Oftalmol; 2021; 137(4):116-122. PubMed ID: 34410066
[TBL] [Abstract][Full Text] [Related]
19. The potential of tear proteomics for diagnosis and management of orbital inflammatory disorders including Graves' ophthalmopathy.
Khazaei H; Khazaei D; Verma R; Ng J; Wilmarth PA; David LL; Rosenbaum JT
Exp Eye Res; 2021 Dec; 213():108813. PubMed ID: 34742692
[TBL] [Abstract][Full Text] [Related]
20. The Role of Fibrogenesis and Extracellular Matrix Proteins in the Pathogenesis of Graves' Ophthalmopathy.
Chiu HI; Wu SB; Tsai CC
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
